Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Minimal Residual Disease Testing

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

The MRD Testing Collaborative is a collaborative group of stakeholders working to increase awareness of and access to MRD testing in a broad range of blood cancers including CLL. At the ASH (American Society of Hematology) annual meeting last year, Dr. Koffman and others were interviewed for the Be MRD Aware efforts as MRD testing begins a transition from a research tool to becoming an important aid in guiding patient decisions. Please enjoy these two short videos addressing the importance of MRD testing and possible barriers to access.

Originally published in The CLL Society Tribune MRD Special Edition.